NPM1 MUTATION
Clinical trials for NPM1 MUTATION explained in plain language.
Never miss a new study
Get alerted when new NPM1 MUTATION trials appear
Sign up with your email to follow new studies for NPM1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough leukemia: experimental combo enters human testing
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called ziftomenib when combined with standard chemotherapy for people whose acute myeloid leukemia (AML) has returned or not responded to treatment. The study includes adults with specific genetic changes (NPM1 mutation or KMT…
Matched conditions: NPM1 MUTATION
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 17, 2026 06:58 UTC
-
New drug combo aims to keep leukemia in remission after transplant
Disease control Recruiting nowThis study looks at whether menin inhibitors can help prevent leukemia from coming back after a stem cell transplant. About 20 people with certain genetic types of acute leukemia will take these drugs as part of their regular care. Researchers will track how long they stay cancer…
Matched conditions: NPM1 MUTATION
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New drug combo shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests whether adding the experimental drug ziftomenib to standard AML treatments is safe and effective. About 420 adults with specific genetic mutations (NPM1 or KMT2A) will receive one of three drug combinations. The goal is to find the best dose and see i…
Matched conditions: NPM1 MUTATION
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug hopes to keep leukemia away after transplant
Disease control Recruiting nowThis early-phase study tests an experimental drug called ziftomenib in adults with acute myeloid leukemia (AML) who have had a stem cell transplant. The goal is to find a safe dose and see if the drug can help prevent the cancer from coming back. About 22 participants will take t…
Matched conditions: NPM1 MUTATION
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC